News

The Series A financing has been led by Adams Street Partners and Latterell Venture Partners. GLYX-13 is a glycine-site functional partial agonist (GFPA) selective modulator of the NMDA

The company has reported a net income of $1.74m, or $0.07 per diluted share, compared to net income of $5.01m or $0.19 per diluted share, for the same

The double-blind, placebo-controlled, six-week clinical trial (with an active comparator) was conducted in Japan, Korea and Taiwan. Subjects were randomized to four arms – placebo (129 subjects), lurasidone

CYT107 is a critical immune-modulator for immune T-cell recovery and enhancement. The study, known as ELYPSE-7, is a randomised, monocentric, double-blind Phase IIa study evaluating the impact of

The company has reported a net loss of $18.4m, compared to net loss of $16.25m, for the same period last year. The company’s loss from operations was $18.54m,

The company has also treated first patient in the trial. The RPL554 compound is a new bronchodilator/anti-inflammatory drug belonging to a class of drugs known as a mixed

The new label is equipped with a tamper-evident feature in the form of a perforation that provides assurance the autoinjector or pen was not previously opened and that

Almac has implemented biocatalytic technology for metabolite synthesis, isolation and structural identification. Metabolite synthesis is another tool within selectAZyme’s service providing access to both oxidative and glycosylated products.

Paclical is indicated for ovarian cancer and lung cancer. Oasmia has developed a water soluble formulation of Paclitaxel with the retinoid based platform XR-17. Oasmia claims Paclitaxel does